|
Synonyms: clone III | Emgality® | galcanezumab-gnlm | LY-2951742 | LY2951742
galcanezumab is an approved drug (FDA (2018))
Compound class:
Antibody
Comment: Galcanezumab (LY2951742) is a monoclonal antibody targeting calcitonin A and B (CALCA a.k.a. α-CGRP and CALCB a.k.a. β-CGRP respectively), whose anti-migraine and analgesic actions can be applied clinically.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent WO2007076336 [1]. |
| Bioactivity Comments |
| A Fab fragment of the antibody binds human αCGRP with a Kd of 2.09nM and the β isoform with a Kd of 1.22nM [1]. |
| Selectivity at ligand targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
